Alurar rigakafi akan Covid-19 da ƙwayar cuta mai yawa

bincike

A yau an sadaukar da kansa ne ga cutar sikeli, cutar da fuskoki dubu. Wannan daya ne cututtukan jijiyoyin jiki da suka fi shafar samari, da yara. Don haka ci gaban da aka samu a maganin su zai inganta rayuwar wadannan mutanen da cutar ta shafa mahimman iyakoki. Wannan cuta ce mai nakasa jiki.

Godiya ga yawancin binciken da aka gudanar a cikin yaƙi da Covid-19, sun yi aiki ci gaba da nazarin sauran cututtuka, cikinsu akwai wanda ya shafe mu. Kuma shine cewa a cikin ilimin kimiyya an haɗa komai. Zamuyi magana game da waɗannan batutuwan da sauransu akan Ranar Rarraba lewayar Duniya.

Dangantaka tsakanin allurar rigakafin Covid-19 da ƙwayar cuta mai yawa

rigakafin annoba

A cikin watan Janairun wannan shekarar, mujallar Science ta wallafa wani aiki daga wannan kungiyar wacce ta hada allurar rigakafin Pfizer / BioNTech akan Covid-19. Wannan rukuni na masana kimiyya sun sami nasarar gwadawa wani rigakafin RNA (mRNA) wanda ke danne alamomin cututtukan sclerosis da yawa. Gwajin an yi shi ne kawai a cikin dabbobi da kuma samfurin sclerosis da yawa. Dole ne mu yi taka-tsantsan kuma duk da kasancewa kyakkyawan labari da bege, har yanzu akwai sauran aiki a gaba.

Wannan binciken da kungiyar masu kirkirar allurar Pfizer / BioNTech suka yi kan Covid-19, ya zo ya ce (ga mai hankali kan batun) cewa ci gaba da alamun cututtukan sikeli da yawa an kashe su gaba daya, lokacin amfani kafin bayyanar cututtuka su bayyana. Don haka ana iya la'akari da shi azaman magani na rigakafi.

Idan aka yi amfani da su da zarar dabbobi suna da alamomi, sai su koma da yawa. Dabbobi suna murmurewa wani ɓangare ko ma duk motsinsu saboda albarkacin-kumburi, sakamako mara gyarawa. Tabbas wannan labari ne mai matukar bege, amma ba a yi nazarin magani a cikin mutane ba. Wannan gwaji ne na share fage.

Alurar riga kafi kan Covid-19 da marasa lafiya na sclerosis

amintacce ne

Studyungiyar Nazarin lewararren ofwararren lewararren ofungiyar Neuroungiyar Neurology ta Catalan ta tabbatar da cewa alurar rigakafin da aka ba da izinin Covid-19 na da lafiya kuma ba sa cutar da ƙwayar sclerosis da yawa. Alurar riga kafi ba ta canza tsarin aikin magungunan da ake amfani da su don magance cutar. Har ila yau, babu wata shaidar da ke nuna cewa akwai yiwuwar ƙara ɓarkewar cutar bayan karɓar rigakafin.

Saboda haka, akwai tabbaci mai ma'ana cewa Ana iya gudanar da shi ga marasa lafiya masu yawa na sclerosis, duka waɗanda aka kula da waɗanda ba a yi ba Akwai mutane ba tare da magani ba saboda kawai sun kamu da cutar, a matakin farko, tare da alamun rashin lafiya. Abinda kawai ya fice shine cewa ingancin allurar ita kanta zata iya raguwa yayin amfani da kwayoyi tare da mafi girman ƙarfin rigakafi. A wannan ma'anar, suna ba da shawarar neman mafi kyawun lokacin don rigakafin.

Cataungiyar Catalan ta Neurology ta kare cewa ya kamata a yi la’akari da ita yawan da ke cikin haɗari ga marasa lafiya da cututtukan sclerosis da yawa fiye da shekaru 65, tare da babban rashin nakasa kuma wanda dole ne ya karba ko ya sami dusar ƙashi ko kuma rigakafin rigakafi. Wannan fallasa yana cikin takaddar: Shawarwari kan allurar riga kafi ga COVID-19 ga marasa lafiya da ke da MS.

Sauran Ci Gaban Nazarin Maganin Ciwon Sikila da Yawa

makircin sclerosis da yawa

Wannan dangantakar tsakanin allurar rigakafin RNA, wacce kuma za a iya amfani da tsarinta ga marasa lafiya masu fama da cututtukan sikila, ba ita ce kawai ci gaban da ake samu a jiyya ba. Aiki na ci gaba da bunkasa jiyya da ke maye gurbin oligodendrocytes da myelin.

Har yanzu akwai magunguna fiye da 10 da aka yarda da su don cutar rashin kumburi a cikin mutane. Waɗannan su ne magungunan rigakafi, wanda ke rage saurin cutar, amma ba zai iya dakatar da shi kwata-kwata, ko warkar da shi ba. Wadannan kwayoyi galibi suna da mahimman sakamako masu illa, kamar rage tasirin kariya akan sauran ƙwayoyin cuta, sama da tsada ga tsarin kiwon lafiya.

A wannan ma'anar, binciken da aka gudanar a Amurka ya kammala cewa Maganin gyaran cutar yana da alaƙa da ƙarancin kuɗaɗen farashi, kai tsaye da kuma kai tsaye don tsarin kiwon lafiya. Kashi 69% na wannan tanadin ya dace da farashin kiwon lafiya kai tsaye da sauran kashi 31% zuwa asara cikin yawan aiki.


Abubuwan da ke cikin labarin suna bin ka'idodinmu na ka'idojin edita. Don yin rahoton kuskure danna a nan.

Kasance na farko don yin sharhi

Bar tsokaci

Your email address ba za a buga.

*

*

  1. Mai alhakin bayanan: Miguel Ángel Gatón
  2. Dalilin bayanan: Gudanar da SPAM, gudanar da sharhi.
  3. Halacci: Yarda da yarda
  4. Sadarwar bayanan: Ba za a sanar da wasu bayanan ga wasu kamfanoni ba sai ta hanyar wajibcin doka.
  5. Ajiye bayanai: Bayanin yanar gizo wanda Occentus Networks (EU) suka dauki nauyi
  6. Hakkoki: A kowane lokaci zaka iyakance, dawo da share bayanan ka.